Light-adjustable lens continues to impress

Article

Early experience from a pilot study shows that spherocylindrical error after cataract surgery can be corrected with a proprietary light-adjustable lens (LAL; Calhoun Vision) to improve uncorrected visual acuity (UCVA), said Arturo S. Chayet, MD.

Early experience from a pilot study shows that spherocylindrical error after cataract surgery can be corrected with a proprietary light-adjustable lens (LAL; Calhoun Vision) to improve uncorrected visual acuity (UCVA), said Arturo S. Chayet, MD.

Dr Chayet, medical director, Codet Laser Vision Institute, Tijuana, Mexico, presented results from the first six patients who underwent small-incision surgery and implantation of the lens followed by treatment for residual spherocylindrical error. All patients had at least two to three weeks of post-adjustment follow-up.

Mean cylinder prior to adjustment was –1.37 D and it was reduced to a mean of –0.50 D. The mean vectorial cylinder adjustment was –0.87 D.

Post-adjustment UCVA was improved compared with the pre-adjustment level in all eyes and was 20/25 or better. No eyes lost BCVA. Topographic evaluations showed no change in the corneal maps while wavefront aberrometry illustrated the reduction of astigmatism.

"There are many potential advantages of toric adjustment with the [lens]," Dr Chayet said. "It offers a precise method for correcting sphere and cylinder while allowing surgeons to maintain their same technique with respect to incision location and IOL placement. In addition, the spatial profile of it can be written along with multifocal corrections.

"With available technology, it is possible to correct up to 2.5 D of cylinder at the spectacle plane," he concluded. "The next step will be to refine the nomograms to achieve higher levels of correction."

 

Read

ASCRS 2008 meeting highlights.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.